Royalty Pharma PLCNASDAQ:RPRX
- LAST PRICE28.4650
- TODAY'S CHANGE (%)0.2750 (0.9755%)
- Bid / Lots28.4600/ 5
- Ask / Lots28.4700/ 6
- Open / Previous Close28.2600 / 28.1900
- Day Range
- 52 Week Range
- Volume364,127
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RPRX |
|---|---|---|
| 09:32 ET | 21272 | 28.355 |
| 09:34 ET | 3166 | 28.36 |
| 09:36 ET | 5579 | 28.29 |
| 09:38 ET | 2050 | 28.27 |
| 09:39 ET | 5291 | 28.25 |
| 09:41 ET | 3333 | 28.26 |
| 09:43 ET | 3292 | 28.3 |
| 09:45 ET | 7326 | 28.31 |
| 09:48 ET | 6052 | 28.3 |
| 09:50 ET | 3083 | 28.285 |
| 09:52 ET | 2673 | 28.285 |
| 09:54 ET | 7377 | 28.275 |
| 09:56 ET | 8466 | 28.28 |
| 09:57 ET | 2372 | 28.29 |
| 09:59 ET | 5191 | 28.35 |
| 10:01 ET | 5372 | 28.37 |
| 10:03 ET | 4454 | 28.295 |
| 10:06 ET | 9396 | 28.3 |
| 10:08 ET | 4028 | 28.325 |
| 10:10 ET | 4539 | 28.295 |
| 10:12 ET | 9772 | 28.325 |
| 10:14 ET | 5257 | 28.33 |
| 10:15 ET | 3034 | 28.345 |
| 10:17 ET | 10755 | 28.35 |
| 10:19 ET | 5230 | 28.335 |
| 10:21 ET | 4409 | 28.35 |
| 10:24 ET | 1943 | 28.36 |
| 10:26 ET | 2939 | 28.39 |
| 10:28 ET | 5513 | 28.41 |
| 10:30 ET | 5731 | 28.39 |
| 10:32 ET | 3763 | 28.38 |
| 10:33 ET | 11564 | 28.31 |
| 10:35 ET | 3757 | 28.345 |
| 10:37 ET | 2111 | 28.36 |
| 10:39 ET | 5291 | 28.375 |
| 10:42 ET | 1265 | 28.375 |
| 10:44 ET | 3686 | 28.375 |
| 10:46 ET | 1289 | 28.3711 |
| 10:48 ET | 3975 | 28.385 |
| 10:50 ET | 3329 | 28.395 |
| 10:51 ET | 3763 | 28.405 |
| 10:53 ET | 4540 | 28.395 |
| 10:55 ET | 4952 | 28.38 |
| 10:57 ET | 948 | 28.385 |
| 11:00 ET | 3338 | 28.4 |
| 11:02 ET | 3225 | 28.395 |
| 11:04 ET | 3230 | 28.4039 |
| 11:06 ET | 6703 | 28.405 |
| 11:08 ET | 1265 | 28.415 |
| 11:09 ET | 2793 | 28.405 |
| 11:11 ET | 1408 | 28.415 |
| 11:13 ET | 3737 | 28.435 |
| 11:15 ET | 1527 | 28.445 |
| 11:18 ET | 5515 | 28.48 |
| 11:20 ET | 6214 | 28.485 |
| 11:22 ET | 450 | 28.49 |
| 11:24 ET | 3925 | 28.49 |
| 11:26 ET | 2094 | 28.49 |
| 11:27 ET | 2969 | 28.47 |
| 11:29 ET | 2270 | 28.465 |
| 11:31 ET | 1009 | 28.465 |
| 11:33 ET | 2200 | 28.465 |
Sep 20, 2024
DJ S&P 500 Futures Decline In Premarket Trading; FedEx, Frontline Lag, from 7:30AM ET on Friday Sep 20, 2024 by Dow Jones
7:30AM ET on Friday Sep 20, 2024 by Dow Jones
Sep 18, 2024
DJ S&P 500 Futures Up In Premarket Trading; Manhattan Associates, Casella Waste Sys Lag, from 7:30AM ET on Wednesday Sep 18, 2024 by Dow Jones
7:30AM ET on Wednesday Sep 18, 2024 by Dow Jones
Sep 3, 2024
Press Release: Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement, from 5:14PM ET on Tuesday Sep 03, 2024 by Dow Jones
5:14PM ET on Tuesday Sep 03, 2024 by Dow JonesRoyalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement, from 5:14PM ET on Tuesday Sep 03, 2024 by Dow Jones
5:14PM ET on Tuesday Sep 03, 2024 by Dow JonesPress Release: Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement, from 5:06PM ET on Tuesday Sep 03, 2024 by Dow Jones
5:06PM ET on Tuesday Sep 03, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Royalty Pharma PLC | 16.7B | 18.9x | +1.83% |
Amneal Pharmaceuticals Inc | 2.6B | -13.5x | --- |
Endo Inc | 1.9B | 0.4x | --- |
Catalent Inc | 10.9B | -10.5x | --- |
Jazz Pharmaceuticals PLC | 6.8B | 19.4x | -3.53% |
Mallinckrodt PLC | 1.6M | 0.0x | --- |
Company Information
Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio consists of royalties on over 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates. Its development-stage product candidates include Aficamten, Ampreloxetine, BCX10013, MK-8189, Ecopipam, Olpasiran, Pelabresib, KarXT, Pelacarsen, Seltorexant, Trontinemab, TEV-'749, Tulmimetostat and Vanzacaftor. Its subsidiaries include Royalty Pharma Holdings Ltd., Royalty Pharma Investments and others.
Contact Information
- Headquarters
- 110 East 59th StreetNEW YORK, NY, United States 10022
- Phone
- 212-883-0200
- Fax
- ---
Executives
- Chairman of the Board, Chief Executive Officer
- Pablo Legorreta
- Vice Chairman, Executive Vice President
- Christopher Hite
- Chief Financial Officer, Executive Vice President
- Terrance Coyne
- Executive Vice President - Investments and Chief Legal Officer
- George Lloyd
- Executive Vice President - Head of Human Capital
- Molly Sawaya
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $16.7B |
|---|---|
Revenue (TTM) | $2.2B |
Shares Outstanding | 593.5M |
Dividend Yield | 2.95% |
Annual Dividend Rate | 0.8400 USD |
Ex-Dividend Date | 08-16-24 |
Pay Date | 09-13-24 |
Beta | 0.46 |
EPS | $1.50 |
Book Value | $14.61 |
P/E Ratio | 18.9x |
Price/Sales (TTM) | 7.5 |
Price/Cash Flow (TTM) | 19.9x |
Operating Margin | 42.91% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
